Observational study to characterize treatment-resistant depression in Germany, France and the United Kingdom: analysis of real-world data collected through a survey of healthcare professionals

References

• Liu Q, He H, Yang J, et al. Changes in the global burden of depression from 1990 to 2017: findings from the global burden of disease study. J Psychiatr Res. 2020;126:134–140.
   PubMed Web of Science ®Google Scholar
• Luo Y, Zhang S, Zheng R, et al. Effects of depression on heart rate variability in elderly patients with stable coronary artery disease. J Evid Based Med. 2018;11(4):242–245.
   PubMedGoogle Scholar
• Seligman F, Nemeroff CB. The interface of depression and cardiovascular disease: therapeutic implications. Ann N Y Acad Sci. 2015;1345:25–35.
   PubMed Web of Science ®Google Scholar
• Stringaris A. Editorial: what is depression? J Child Psychol Psychiatry. 2017;58(12):1287–1289.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. 2013. Guideline on clinical investigation of medicinal products in the treatment of depression. EMA/CHMP/185423/2010 Rev 2. London (UK): European Medicines Agency.
   Google Scholar
• Brown S, Rittenbach K, Cheung S, et al. Current and common definitions of treatment-resistant depression: findings from a systematic review and qualitative interviews. Can J Psychiatry. 2019;64(6):380–387.
   PubMed Web of Science ®Google Scholar
• McLachlan G. Treatment resistant depression: what are the options? BMJ. 2018;363:k5354.
   PubMedGoogle Scholar
• Yrondi A, Bennabi D, Haffen E, et al. Treatment-resistant depression in a real-world setting: first interim analysis of characteristics, healthcare resource use, and utility values of the FondaMental cohort. Brain Sci. 2020;10(12):962.
   PubMed Web of Science ®Google Scholar
• Brenner P, Nygren A, Hägg D, et al. Health care utilisation in treatment-resistant depression: a Swedish population-based cohort study. Int J Psychiatry Clin Pract. 2021:1–8. DOI:10.1080/13651501.2021.2003405
   PubMed Web of Science ®Google Scholar
• Jaffe DH, Rive B, Denee TR. The humanistic and economic burden of treatment-resistant depression in Europe: a cross-sectional study. BMC Psychiatry. 2019;19(1):247.
   PubMed Web of Science ®Google Scholar
• Perugi G, Calò P, De Filippis S, et al. Clinical features and outcomes of 124 Italian patients with treatment resistant depression: a real-world, prospective study. Front Psychiatry. 2021;12:769693.
   PubMed Web of Science ®Google Scholar
• De Carlo V, Calati R, Serretti A. Socio-demographic and clinical predictors of non-response/non-remission in treatment resistant depressed patients: a systematic review. Psychiatry Res. 2016;240:421–430.
   PubMed Web of Science ®Google Scholar
• Souery D, Oswald P, Massat I, et al. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry. 2007;68(7):1062–1070.
   PubMed Web of Science ®Google Scholar
• Solano P, Ustulin M, Pizzorno E, et al. A google-based approach for monitoring suicide risk. Psychiatry Res. 2016;246:581–586.
   PubMed Web of Science ®Google Scholar
• Dunner DL, Rush AJ, Russell JM, et al. Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression. J Clin Psychiatry. 2006;67(5):688–695.
   PubMed Web of Science ®Google Scholar
• Hantouche E, Angst J, Azorin J-M. Explained factors of suicide attempts in major depression. J Affect Disord. 2010;127(1–3):305–308.
   PubMed Web of Science ®Google Scholar
• Nelsen MR, Dunner DL. Clinical and differential diagnostic aspects of treatment-resistant depression. J Psychiatr Res. 1995;29(1):43–50.
   PubMed Web of Science ®Google Scholar
• de Graaf R, Bruffaerts JP, Lépine G, et al. Risk factors for suicidality in Europe: results from the ESEMED study. J Affect Disord. 2007;101(1–3):27–34.
   PubMed Web of Science ®Google Scholar
• Chen YW, Dilsaver SC. Lifetime rates of suicide attempts among subjects with bipolar and unipolar disorders relative to subjects with other axis I disorders. Biol Psychiatry. 1996;39(10):896–899.
   PubMed Web of Science ®Google Scholar
• Nock MK, Borges G, Bromet EJ, et al. Cross-national prevalence and risk factors for suicidal ideation, plans and attempts. Br J Psychiatry. 2008;192(2):98–105.
   PubMed Web of Science ®Google Scholar
• Baldessarini RJ, Innamorati M, Erbuto D, et al. Differential associations of affective temperaments and diagnosis of major affective disorders with suicidal behavior. J Affect Disord. 2017;210:19–21.
   PubMed Web of Science ®Google Scholar
• de Aguiar Ferreira A, Vasconcelos AG, Neves FS, et al. Affective temperaments and antidepressant response in the clinical management of mood disorders. J Affect Disord. 2014;155:138–141.
   PubMed Web of Science ®Google Scholar
• Papakostas GI. Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder. J Clin Psychiatry. 2009;70(Suppl 6):16–25.
   PubMed Web of Science ®Google Scholar
• Denee T, Kerr C, Ming T, et al. Current treatments used in clinical practice for major depressive disorder and treatment resistant depression in England: a retrospective database study. J Psychiatr Res. 2021;139:172–178.
   PubMed Web of Science ®Google Scholar
• Mahase E. Esketamine is approved in Europe for treating resistant major depressive disorder. BMJ. 2019;367:l7069.
   PubMedGoogle Scholar
• Heerlein K, Young AH, Otte C, et al. Real-world evidence from a European cohort study of patients with treatment resistant depression: Baseline patient characteristics. J Affect Disord. 2021;283:115–122.
   PubMed Web of Science ®Google Scholar
• Public Policy Committee, International Society of Pharmacoepidemiology. Guidelines for good pharmacoepidemiology practice (GPP). Pharmacoepidemiol Drug Saf. 2016;25(1):2–10.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Good pharmacovigilance practices [Internet] [cited 2021 Dec 15]. Available from: https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/good-pharmacovigilance-practices
   Google Scholar
• European Network of Centres for Pharmacoepidemiology and Pharmacovigilance [Internet] [cited 2021 Dec 15]. Available from: https://www.encepp.eu/
   Google Scholar
• Taylor RW, Marwood L, Oprea E, et al. Pharmacological augmentation in unipolar depression: a guide to the guidelines. Int J Neuropsychopharmacol. 2020;23(9):587–625.
   PubMed Web of Science ®Google Scholar
• Kubitz N, Mehra M, Potluri RC, et al. Characterization of treatment resistant depression episodes in a cohort of patients from a US commercial claims database. PLOS One. 2013;8(10):e76882.
   PubMed Web of Science ®Google Scholar
• Wu B, Cai Q, Sheehan JJ, et al. An episode level evaluation of the treatment journey of patients with major depressive disorder and treatment-resistant depression. PLOS One. 2019;14(8):e0220763.
   PubMed Web of Science ®Google Scholar
• NICE. Depression in adults: treatment and management. 2022. Available from: https://www.nice.org.uk/guidance/ng222
   Google Scholar
• Olchanski N, McInnis Myers M, Halseth M, et al. The economic burden of treatment-resistant depression. Clin Ther. 2013;35(4):512–522.
   PubMed Web of Science ®Google Scholar
• Cepeda MS, Reps J, Fife D, et al. Finding treatment-resistant depression in real-world data: how a data-driven approach compares with expert-based heuristics. Depress Anxiety. 2018;35(3):220–228.
   PubMed Web of Science ®Google Scholar